Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	6 Months Ended
	Sep. 26, 2014	Sep. 27, 2013
Cash flows from operating activities:
Net loss	$ (636,000)	$ (1,503,000)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	336,000	463,000
Amortization of intangible assets	386,000	509,000
Amortization of debt discount	74,000	96,000
Stock based compensation expense	37,000	70,000
Change in fair value of warrant liability	(91,000)	89,000
Changes in operating assets and liabilities:
Accounts receivable – net	623,000	(674,000)
Inventories	(51,000)	(712,000)
Prepaid expenses and other assets	(316,000)	15,000
Accounts payable and accrued expenses	(662,000)	1,172,000
Net cash used in operating activities	(300,000)	(475,000)
Cash flows from investing activities:
Capital expenditures	(132,000)	(93,000)
Proceeds from sale of equipment	125,000
Patent expenditures	(130,000)	(127,000)
Net cash used in investing activities	(137,000)	(220,000)
Cash flows from financing activities:
Net proceeds or (payments) on bank line of credit	(946,000)	1,251,000
Payments on bank term loan	(139,000)	(167,000)
Payments on MEDC/MSF term loans		(276,000)
Payments on PFG term loan	(357,000)	(357,000)
Payments on capital lease	(9,000)	(3,000)
Taxes paid on net share settlement		(1,000)
Net proceeds from issuance of Class A Common Stock	2,914,000
Net cash provided by financing activities	1,463,000	447,000
Net increase (decrease) in cash and cash equivalents	1,026,000	(248,000)
Cash and cash equivalents at beginning of period	120,000	619,000
Cash and cash equivalents at end of period	1,146,000	371,000
Supplemental disclosure of cash flow information:
Cash paid for interest	167,000	193,000
Supplemental disclosure of non-cash investing and financing activities:
Acquisition of equipment through-capital lease		$ 50,000